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Background: Decline in fertility seen in Cannabis sativa (CS) consumers has been related to 
its influence on reproductive hormones but the mechanism(s) involved is not fully understood. 
Moreover, the possible beneficial or detrimental effect of melatonin and vitamin C on 
cannabis-associated effects on reproductive hormones is yet to be investigated and necessitated 
this study. Methods: Fifty-five (55) male albino rats (250-300g) were randomly divided in a 
blinded fashion into 5 oral treatment groups as follow: Group I (control, n=5) received 10% 
ethanol (1 ml/kg) for 30 days. Groups 2, 3, and 4 consisted of 15 rats each that were 
subdivided to receive CS (2 mg/kg) only, CS (2 mg/kg)+melatonin (4 mg/kg), and CS (2 
mg/kg)+vitamin C (1.25 g/kg) respectively for 20-, 30-, or 40 days (n=5 rats each). Group V 
(n=5) received CS (2 mg/kg) + melatonin (4 mg/kg)+vitamin C (1.25 g/kg) for 30 days. 
Results: The CS reduced gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), 
and testosterone but increased estradiol and prolactin. In addition, co-administration of CS with 
melatonin and vitamin C abolished the effect of cannabis on these parameters when combined 
but not when administered separately (except for prolactin and GnRH). Conclusion: Cannabis 
causes downregulation of hypothalamic-pituitary-gonadal axis, endocrine disruption, and 
hyperprolactinemia. These effects (except hyperprolactinemia) could be reversed by melatonin 





Cannabis sativa (marijuana), the most widely used 
illicit drug in the world, is a “chemical factory”, 
producing more than 500 different chemical 
compounds (Rosales-Corral et al., 2015). Various 
mental health problems like impaired memory and 
attention, reduced motor skills, anxiety, and addiction 
have been observed in some of its users (Degenhardt et 
al., 2010; Hall and Solowij, 1998). Its legalization has 
been increasing globally due to its documented 
beneficial effects in the management of many diseases 
like cancer (Velasco et al., 2016), inflammation (Juknat 
et al., 2016), pain (Lynch, 2016), and epilepsy (Tzadok 
et al., 2016). 
Although it is well known that chronic marijuana use 
transiently decreases male fertility in animal models 
and humans (Murphy et al., 1994), the mechanism 
involved remain unclear. Some studies have implicated 
reduction in some male reproductive parameters such 
as testosterone secretion, sperm production, sperm 
motility, sperm viability, luteinizing and follicle 
stimulating hormone as possible culprits (Nahas et al., 
2002; Schuel and Burkman, 2005; Alagbonsi et al., 
2016). 
Vitamin C (ascorbate) acts as a potent water-soluble 
anti-oxidant in biological fluids by scavenging 
physiologically relevant reactive oxygen species and 
reactive nitrogen species (Halliwell, 1996). Melatonin 
(N-acetyl-5-methoxy-tryptamine) is the main pineal 
hormone synthesized from tryptophan, predominantly 
at night (Arendt, 1995). Melatonin is critical for the 
regulation of circadian and seasonal changes in various 
aspects of physiology and neuroendocrine function 
(Pevet et al., 2002). Being a potent naturally occurring 
anti-oxidant (Zhang and Zhang, 2014), its beneficial 
effect on male fertility would be expected as there are 
numerous links between oxidative stress and male 
factor infertility (El-Tohamy, 2012). However, decline 
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in progression of spermatogenesis, testosterone, human 
chorionic gonadotropin binding sites, and luteinizing 
hormones (LH) at the end of juvenile period have been 
reported in immature male rats treated with melatonin 
(Olivares et al., 1989). Even in female mammals, it has 
been evaluated as an oral contraceptive due to its ability 
to inhibit pre-ovulatory LH surge (McElhinny et al., 
1996). 
 
Because melatonin is produced endogenously and also 
occurs naturally in some foods (Reiter et al., 2015), it is 
being sold as a dietary supplement in the U.S. under the 
dietary supplement Health and Education Act of 1994 
without pre-market approval from the Food and Drug 
Administration. Vitamin C has also been grossly 
abused by users because of its wide perception as an 
anti-oxidant. Moreover, legislation and 
decriminalization of cannabis possession is increasing 
worldwide. This will lead to an increasing use of 
cannabis and consequently an increase in infertility. 
There is therefore the need to be proactive in solving 
the reproductive health problems that may arise from 
increasing use of cannabis due to its decriminalization. 
 
We have recently shown that the cannabis-induced 
gonadotoxicity is partly mediated by oxidative stress. 
Furthermore, melatonin and vitamin C deteriorated 
cannabis-induced gonadotoxicity when administered 
separately but ameliorated it when combined in rats 
(Alagbonsi et al., 2016). However, the mechanism 
involved in the regulation of reproductive hormones by 
cannabis is not fully understood. Moreover, the 
possible beneficial or detrimental effect of melatonin 
and vitamin C on cannabis-associated effects on 
reproductive hormones is yet to be investigated and is 
of interest to us. 
 
MATERIALS AND METHODS 
Animals 
Fifty five male albino rats (250-300g) obtained from 
the Department of Biochemistry, University of Ilorin, 
Kwara State, Nigeria, were housed at room temperature 
with free access to food and tap water ad libitum and 
maintained on a daily light/dark cycle. In addition to 
experimental protocol approval by our institutional 
ethics committee, “principles of laboratory animal care 
(NIH publication No. 85-23, revised 1985)” were 
followed. 
 
Extraction of Cannabis Sativa leaves 
Cannabis sativa leaves (CS), which was kindly donated 
by National Drug Law Enforcement Agency (NDLEA), 
Nigeria, for research purpose only, was done with 98% 
ethanol in Soxhlet apparatus for 4-8 hours as previously 
described (Dixit et al., 1974; Mandal and Das, 2010; 
Alagbonsi et al., 2016). Its percentage yield was 21.2%. 
 
Experimental protocol 
After 2 weeks acclimatization to their new environment 
with standard laboratory diet and water given ad 
libitum, the animals were randomly divided in a blinded 
fashion into 5 oral treatment groups as follow: Group I 
(control, n=5) received 10% ethanol (1 ml/kg) for 30 
days. Groups 2, 3, and 4 consisted of 15 rats each that 
were subdivided to receive CS (2 mg/kg) only, CS (2 
mg/kg)+melatonin (4 mg/kg), and CS (2 
mg/kg)+vitamin C (1.25 g/kg) respectively for 20-, 30-, 
or 40 days (n=5 rats each). Group V (n=5) received CS 
(2 mg/kg)+melatonin (4 mg/kg)+vitamin C (1.25 g/kg) 
for 30 days.  
 
After determining the lethal dose that killed 50% of the 
treated animals (Yassa et al., 2010), the 2 mg/kg dose 
of CS was arrived at as the tenth of its LD50. Ethanol 
was used to dissolve CS extract, while normal saline 
was used to dissolve melatonin and vitamin C 
(Biopharma Nigeria Ltd.). Animals were sacrificed a 
day after the last treatment under ketamine anesthesia 
and plasma was collected from each sample and 
preserved at -20 °C. 
 
Estimation of reproductive hormones 
Enzyme-linked immunosorbent assays of Testosterone 
(Monobind Inc., Lake Forest, CA, USA. Product Code: 
3725-300), Estadiol (Monobind Inc., Lake Forest, CA, 
USA. Product Code: 4925-300), Progesterone 
(Monobind Inc., Lake Forest, CA, USA. Product Code: 
4825-300), Luteinizing Hormone (Monobind Inc., Lake 
Forest, CA, USA. Product Code: 625-300), Follicle 
Stimulating Hormone (Monobind Inc., Lake Forest, 
CA, USA. Product Code: 425-300), Prolactin 
(Monobind Inc., Lake Forest, CA, USA. Product Code: 
725-300), Gonadotropin Releasing Hormone 
(Elabscience, catalog No: E-EL-R0451c) were done 
spectrophotometrically (Spectramax plus, Molecular 




Data were analyzed with one-way ANOVA using SPSS 
version 16.0 (IBM Corporation, Armonk, NY, USA), 
followed by a post-hoc Least Significance Difference 
(LSD) test for multiple comparisons. Data were 
presented as the Mean ± SEM. p values ≤0.05 were 
considered statistically significant. 
 
RESULTS 
Effects of cannabis with(out) melatonin and/or vitamin 
C on testosterone in rats 
Cannabis administration to rats caused reductions in 
testosterone concentrations at 20 days (p<0.01), 30 
days (p<0.001), and 40 days (p<0.01) when compared 
Cannabis, melatonin, vitamin C and hormonal toxicity 
16                                         J. Afr. Ass. Physiol. Sci. 4 (1): July,  2016                                Alagbonsi and Olayaki                         
 
to control. Administration of cannabis+melatonin 
caused more reductions in testosterone concentrations 
than that caused by cannabis alone at 20 days 
(p<0.001), 30 days (p<0.001), and 40 days (p<0.001) 




Fig.1: Testosterone concentration in rats given cannabis with(out) melatonin and/or vitamin C. Values are expressed as 
Mean±S.E.M (n=5). **p<0.01, ***p<0.001 vs. control; ap<0.05 vs. cannabis 20 days; ###p<0.001 vs. cannabis+melatonin 30 
days; vvp<0.01 vs. cannabis+vitamin C 20 days; ££p<0.01 vs. cannabis 30 days; pp<0.05, ppp<0.01 vs. cannabis+melatonin 30 
days, $p<0.05 vs. cannabis+vitamin C 30 days; @p<0.05 vs. cannabis 40 days; µµp<0.01 vs. cannabis+melatonin 40 days; 






Fig.2: Estradiol concentration in rats given cannabis with(out) melatonin and/or vitamin C. Values are expressed as 
Mean±S.E.M (n=5). *p<0.05, **p<0.01, ***p<0.001 vs. control; ap<0.05, aap<0.01 vs. cannabis 20 days; #p<0.05 vs. 
cannabis+melatonin 20 days; vp<0.05, vvp<0.01 vs. cannabis+vitamin C 20 days; ££p<0.01, £££p<0.001 vs. cannabis 30 days; 
ppp<0.01, pppp<0.001 vs. cannabis+melatonin 30 days, $$$p<0.001 vs. cannabis+vitamin C 30 days; @p<0.05, @@p<0.01 vs. 
cannabis 40days; µµµp<0.001 vs. cannabis+melatonin 40 days. 
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concentrations in rats that received cannabis+vitamin C 
were lower at 20 days (p<0.001), 30 days (p<0.01), and 
40 days (p<0.001) than in the control but comparable to 
the levels in rats that received cannabis only for similar 
durations. Lastly, the testosterone concentration in rats 
that received cannabis+melatonin+vitamin C is 
comparable to the control level (p>0.05), but 
significantly higher than the concentration in all the 
other treatment subgroups (p<0.05, p<0.01, p<0.001) 
(Figure 1). This shows that the reduced testosterone in 
rats receiving cannabis could be prevented by 
melatonin and vitamin C only when combined but not 









Fig. 4: Luteinizing Hormone (LH) concentration in rats given cannabis with(out) melatonin and/or vitamin C. Values are 
expressed as Mean±S.E.M (n=5). *p<0.05, **p<0.01, ***p<0.001 vs. control; aaap<0.001 vs. cannabis 20 days; ##p<0.01, 
###p<0.001 vs. cannabis+melatonin 20 days; vvvp<0.001 vs. cannabis+vitamin C 20 days; £££p<0.001 vs. cannabis 30 days; 
pppp<0.001 vs. cannabis+melatonin 30 days, $$$p<0.001 vs. cannabis+vitamin C 30 days; @@@p<0.001 vs. cannabis 40 days; 
µµµp<0.001 vs. cannabis+melatonin 40 days; ßßßp<0.001 vs. cannabis+vitamin C 40 days.  
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Fig. 5: Follicle Stimulating Hormone (FSH) concentration in rats given cannabis with(out) melatonin and/or vitamin C. Values 
are expressed as Mean±S.E.M (n=5). *p<0.05 vs. control; ap<0.05, aap<0.01 vs. cannabis 20 days; ###p<0.001 vs. 
cannabis+melatonin 30 days; vp<0.05, vvp<0.01, vvvp<0.001 vs. cannabis+vitamin C 20 days; £p<0.05 vs. cannabis 30 days; 
ppp<0.01 vs. cannabis+melatonin 30 days, $p<0.05, $$p<0.01, $$$p<0.001 vs. cannabis+vitamin C 30 days; @p<0.05, 






Fig. 6: Prolactin concentration in rats given cannabis with(out) melatonin and/or vitamin C. Values are expressed as 
Mean±S.E.M (n=5). ***p<0.001 vs. control; aaap<0.001 vs. cannabis 20 days; ###p<0.001 vs. cannabis+melatonin 20 days; 
vvvp<0.001 vs. cannabis+vitamin C 20 days; £££p<0.001 vs. cannabis 30 days; ppp<0.01 vs. cannabis+melatonin 30 days, 
$$p<0.01 vs. cannabis+vitamin C 30 days; µp<0.05 vs. cannabis+melatonin 40 days. 
 
Effects of cannabis with(out) melatonin and/or vitamin 
C on estradiol in rats 
Cannabis administration to rats caused increase in 
estradiol concentrations at 20 days (p<0.001), 30 days 
(p<0.001), and 40 days (p<0.001) when compared to 
control. Rats that received cannabis+melatonin also had 
increased estradiol concentrations at 20 days (p<0.01), 
30 days (p<0.001) and 40 days (p<0.001) when 
compared to control. The testosterone level in rats that 
received cannabis+melatonin for 30 days and 40 days 
are higher, albeit insignificant (p>0.05), than in rats 
that received cannabis only for same duration.  
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Similarly, estradiol concentrations in rats that received 
cannabis+vitamin C for 20 days (p<0.01), 30 days 
(p<0.05), and 40 days (p<0.05) were higher than in 
control. It is however noteworthy that the extent of 
increases in estradiol level observed in 
cannabis+vitamin C subgroups are smaller compared to 
cannabis subgroups (p>0.05, p<0.01, p<0.05) and 
cannabis+melatonin subgroups (p>0.05, p<0.01, 
p<0.001) at 20 days, 30 days, and 40 days respectively. 
Lastly, rats that received cannabis+melatonin+vitamin 
C had estradiol concentration that is comparable to the 
control level (p>0.05), and below the level in cannabis 
20 days (p<0.01), cannabis+melatonin 20 days 
(p<0.05), cannabis+vitamin C 20 days (p<0.05), 
cannabis 30 days (p<0.001), cannabis+melatonin 30 
days (p<0.001), cannabis 40 days (p<0.01), and 
cannabis+melatonin 40 days (p<0.001) subgroups 
(Figure 2). This shows that the increased estradiol in 
rats receiving cannabis could be prevented by 
melatonin and vitamin C only when combined but not 
when separated. 
 
Effects of cannabis with(out) melatonin and/or vitamin 
C on progesterone in rats 
Cannabis administration to rats with(out) 
supplementation with melatonin and/or vitamin C 
caused no significant changes in progesterone 
concentration when compared to control (p>0.05) 
(Figure 3). This suggests that progesterone is 




Fig.7: Gonadotropin Releasing Hormone (GnRH) concentration in rats given cannabis with(out) melatonin and/or vitamin C. 
Values are expressed as Mean±S.E.M (n=5). **p<0.01 vs. control; ap<0.05, aaap<0.001 vs. cannabis 20 days; #p<0.05 vs. 
cannabis+melatonin 20 days; vvp<0.01 vs. cannabis+vitamin C 20 days; £p<0.05 vs. cannabis 30 days; ppp<0.01, pppp<0.001 vs. 
cannabis+melatonin 30 days. 
 
 
Effects of cannabis with(out) melatonin and/or vitamin 
C on luteinizing hormone in rats 
Cannabis administration to rats caused decrease in 
luteinizing hormone levels (LH) at 20 days (p<0.001), 
30 days (p<0.001), and 40 days (p<0.001) when 
compared to control. Rats that received 
cannabis+melatonin also had reduced LH at 20 days 
(p<0.01) and 30 days (p<0.001) when compared to 
control, but increased LH at 40 days when compared to 
control (p<0.05), cannabis 20 days (p<0.001), 
cannabis+melatonin 20 days (p<0.001), 
cannabis+vitamin C 20 days (p<0.001), cannabis 30 
days (p<0.001), cannabis+melatonin 30 days 
(p<0.001), cannabis+vitamin C 30 days (p<0.001), 
cannabis 40 days (p<0.001), and cannabis+vitamin C 
40 days (p<0.001) subgroups. In addition, rats that 
received cannabis+vitamin C also had reduced LH at 
20 days (p<0.001), 30 days (p<0.001), and 40 days 
(p<0.001) when compared to control. Lastly, LH in rats 
that received cannabis+melatonin+vitamin C was 
comparable to the control level (p>0.05), but was 
significantly higher than the level in cannabis 20 days 
(p<0.001), cannabis+melatonin 20 days (p<0.01), 
cannabis+vitamin C 20 days (p<0.001), cannabis 30 
days (p<0.001), cannabis+melatonin 30 days 
(p<0.001), cannabis+vitamin C 30 days (p<0.001), 
cannabis 40 days (p<0.001), and cannabis+vitamin C 
40 days (p<0.001) subgroups (Figure 4). This shows 
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that the reduced LH in rats receiving cannabis could be 
prevented by melatonin and vitamin C only when 
combined but not when separated. 
 
 
Effects of cannabis with(out) melatonin and/or vitamin 
C on follicle stimulating hormone in rats. 
The follicle stimulating hormone concentrations (FSH) 
in rats that received cannabis for 20 days, 30 days, and 
40 days were not significantly different from that of the 
control (p>0.05). Treatment of rats with 
cannabis+melatonin for 20 days (p<0.05) but not for 30 
days (p>0.05) and 40 days (p>0.05) significantly 
reduced FSH when compared to control. Rats that 
received cannabis+vitamin C for 20 days and 30 days 
had higher FSH when compared to control (p>0.05, 
p<0.05), cannabis+melatonin 20 days (p<0.001, 
p<0.001), cannabis 30 days (p<0.05, p<0.05), 
cannabis+melatonin 30 days (p<0.01, p<0.01), 
cannabis 40 days (p<0.001, p<0.001), 
cannabis+melatonin 40 days (p>0.05, p<0.05), and 
cannabis+vitamin C 40 days (p<0.01, p<0.01) 
subgroups respectively. Lastly, rats that received 
cannabis+melatonin+vitamin C had FSH that is 
significantly higher than the control (p<0.05), 
cannabis+melatonin 20 days (p<0.001), cannabis 30 
days (p<0.05), cannabis+melatonin 30 days (p<0.01), 
cannabis 40 days (p<0.001), cannabis+melatonin 40 
days (p<0.05), and cannabis+vitamin C 40 days 
(p<0.01) subgroups (Figure 5). This suggests that 
cannabis treatment did not affect FSH, while 
supplementation with melatonin and vitamin C caused 
some changes in FSH of rats receiving cannabis. 
 
Effects of cannabis with(out) melatonin and/or vitamin 
C on prolactin in rats 
Cannabis administration to rats caused increased 
prolactin concentration at 20 days and 30 days but not 
at 40 days when compared to control (p<0.001), 
cannabis+melatonin 20 days (p<0.001), 
cannabis+vitamin C 20 days (p<0.001), 
cannabis+melatonin 30 days (p<0.001), 
cannabis+vitamin C 30 days (p<0.001), cannabis 40 
days (p<0.001), cannabis+melatonin 40 days 
(p<0.001), cannabis+vitamin C 40 days (p<0.001), and 
cannabis+melatonin+vitamin C 30 days (p<0.001). 
Supplementation of cannabis-treated rats with 
melatonin and/or vitamin C abolished the effects of 
cannabis by reducing the prolactin concentration to 
levels that are comparable to the control (p>0.05) 
(Figure 6). This suggests that cannabis increased 
prolactin level, which was prevented by melatonin 
and/or vitamin C in rats receiving cannabis. 
 
Effects of cannabis with(out) melatonin and/or vitamin 
C on gonadotropin releasing hormone in rats 
Cannabis administration to rats caused reductions in 
gonadotropin releasing hormone concentration (GnRH) 
at 20 days (p<0.01), 30 days (p<0.01), and 40 days 
(p<0.01) when compared to control. Rats that received 
cannabis with melatonin and/or vitamin C had GnRH 
that are comparable to the control level (p>0.05). 
Moreover, rats that received cannabis+melatonin for 30 
days had significantly higher GnRH than the cannabis 
20 days (p<0.001), cannabis+melatonin 20 days 
(p<0.05), cannabis+vitamin C 20 days (p<0.01), 
cannabis 30 days (p<0.001), cannabis+vitamin C 30 
days (p<0.01), cannabis 40 days (p<0.001), 
cannabis+melatonin 40 days (p<0.01), 
cannabis+vitamin C 40 days (p<0.001), and 
cannabis+melatonin+vitamin C (p<0.01) subgroups 
(Figure 7). This suggests that cannabis reduced GnRH, 
which was prevented by melatonin and/or vitamin C in 
rats receiving cannabis. 
 
DISCUSSION 
A high intratesticular level of testosterone has been 
established to be a major prerequisite for sperm 
production and functions including count, motility and 
morphology (Snyder, 2000; Gray et al., 2005). The 
involvement of oxidative stress in cannabis-induced 
gonadotoxicity has recently been shown in rats 
(Alagbonsi et al., 2016). In the present study, 
administration of cannabis to rats caused reduction in 
testosterone, which was sustained with addition of 
either melatonin or vitamin C. The reduction of 
testosterone by cannabis with(out) melatonin or vitamin 
C in this study, in addition to the reduction of paired-
testis-body-weight ratio previously reported by us 
(Alagbonsi et al., 2016), convincingly show that 
hypogonadism is implicated in cannabis-induced 
infertility. It further shows that neither melatonin nor 
vitamin C can reverse the cannabis-induced 
gonadotoxicity when administered separately. 
It is desirable to know what was responsible for the 
hypogonadism observed with administration of 
cannabis with(out) melatonin or vitamin C in this study. 
The testicular secretion of testosterone in males has 
been widely known to be solely controlled by the 
pituitary luteinizing hormone (LH) (Coquelin and 
Desjardins, 1982). By implication, it connotes that 
steady pulsatile secretion of LH is required for high 
testicular Leydig cell testosterone secretion needed for 
sperm production and functions. In the present study, 
administration of cannabis to rats caused reduction in 
LH, which was sustained with separate addition of 
either melatonin or vitamin C. The similarity of this 
trend to the pattern observed for testosterone showed 
that the hypogonadism in rats that received cannabis 
only, or in rats that received either melatonin or vitamin 
C in addition to cannabis, is related to 
hypogonadotropism. 
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It is also of interest to know if the origin of the 
hypogonadotropic hypogonadism observed with 
cannabis treatment in this study is from the 
hypothalamus and the pituitary gland. Because the 
secretion of gonadotropins by pituitary gland is under 
the direct influence of hypothalamic GnRH, 
distinguishing patients with hypogonadotropic 
hypogonadism of pituitary origin from those with 
primary hypothalamic disease is achieved by GnRH 
testing. People with pituitary disease would not respond 
to GnRH, whereas those with hypothalamic disorders 
would secrete LH and FSH normally after 
administration of GnRH (Gingrich, 2010). In our 
present study, melatonin or vitamin treatment reversed 
the cannabis-induced reduction in GnRH to levels that 
are similar to the control (except for rats that received 
cannabis and vitamin C for 40 days) but did not 
concomitantly reverse the cannabis-induced reduction 
in LH. This resistance or lack of responsiveness of the 
pituitary gland to the increased GnRH elicited by co-
administration of cannabis with either melatonin or 
vitamin C shows that the source of cannabis-induced 
hypogonadotropic hypogonadism is from the pituitary 
gland. It also provides additional information that this 
condition can neither be ameliorated by melatonin nor 
vitamin C when administered separately. 
The next thing is to justify what could have 
accounted for the selective effect of cannabis on LH but 
not FSH. The hypothalamic-pituitary-gonadal (HPG) 
axis consists of three parts: gonadotropin-releasing 
hormone (GnRH) neurons projecting from the 
hypothalamus of the brain, gonadotropes in the anterior 
pituitary gland (adenohypophysis) which secrete the 
gonadotropins (LH and FSH), and the Leydig and 
Sertoli cells in the testis of males (Gingrich, 2010). 
GnRH is secreted in pulses from the terminals of GnRH 
neurons and acts on the gonadotropes to induce 
secretion of both LH and FSH, which then act on their 
respective target cells in the gonads (LH on Leydig 
cells; FSH on Sertoli cells) (Kimura and Funabashi, 
1998; Terasawa, 1998). Consequently, gonadal sex 
steroids (testosterone and estradiol) stimulated by LH 
and the protein hormone inhibin B stimulated by FSH 
are released into the bloodstream and provide feedback 
to the hypothalamus and pituitary gonadotropes to 
reduce the secretion of GnRH, LH, and FSH, with 
inhibin selectively inhibiting FSH and the sex steroids 
inhibiting LH secretion (Crowley et al., 1991). The 
responses of pituitary LH and FSH secretion to 
pulsatile hypothalamic GnRH release are radically 
different, with LH release being stimulated very acutely 
(in pulses) by the GnRH pulses, whereas the response 
of FSH is extremely sluggish and takes many hours 
(Crowley et al., 1991; Bousfield et al., 1994). This 
discrepancy has been shown to stem from fundamental 
differences in GnRH-induced synthesis, packaging, and 
release of LH and FSH. Similarly, although the sex 
steroids (testosterone and estradiol) negatively regulate 
LH secretion via effects on both GnRH secretion and 
gonadotrope function, they also exert some little 
negative feedback on FSH secretion; while inhibin 
selectively inhibits FSH secretion. This physiological 
description of the loop provides an explanation to the 
lack of significant change in FSH concentration despite 
reduction in GnRH and testosterone level following 
cannabis treatment. However, measurement of inhibin 
B, which is a limitation of this study, will provide 
further explanation to the unchanged FSH observed 
with cannabis in this study. 
Endocrine disruptors are estrogen-like and/or 
anti-androgenic chemicals in the environment that have 
potentially hazardous effects on male reproductive axis 
resulting in infertility and on other hormonal dependent 
reproductive functions causing erectile dysfunction 
(ED) (Sikka and Wang, 2008). Endocrine disruptors are 
characterized by causing increased estrogen or reduced 
androgen or combination of both effects. Treatment 
with various kinds of endocrine disruptors have been 
reported to cause germ cell and Leydig cell damage, 
down-regulation of HPG axis, and reduction of fertility, 
libido, spermatogenesis, and accessory sex glands 
weight (Sikka and Wang, 2008). The present study 
further demonstrates that the cannabis-induced 
infertility reported by us, the mechanism of which was 
partly explained by us through oxidative stress 
(Alagbonsi et al., 2016), could additionally be as a 
result of its endocrine disrupting ability due to the 
observed estrogenic and anti-androgenic effects. This 
study further adds cannabis to the comprehensive lists 
of endocrine disruptors. It is also noteworthy that the 
cannabis-induced endocrine disruption could only be 
reversed by melatonin and vitamin C when combined 
but not when administered separately in rats. 
The observation of increased GnRH and 
reduced LH elicited by melatonin or vitamin C in 
cannabis-treated rats was surprising to us. Although it 
is generally held that testosterone, the major secretory 
product of the testis, is the primary inhibitor of LH 
secretion in men, a number of testicular secretory 
products, including estrogens and other androgens, 
have the ability to inhibit LH secretion. Estradiol, a 
potent estrogen, is produced both from the testis and 
from peripheral conversion of androgens and androgen 
precursors and is a much more potent inhibitor of LH 
secretion (approximately 1000-fold) in males. Also, 
testosterone acts primarily to feedback at the level of 
the hypothalamus whereas estrogens provide feedback 
to the pituitary to modulate the gonadotropin secretion 
response to each GnRH surge (Gingrich, 2010). In this 
study, co-administration of cannabis with either 
melatonin or vitamin C maintained the testosterone to 
the level lower than the control but comparable to the 
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rats that received cannabis only, whereas reversed the 
trend for GnRH. In addition, we observed reductions in 
LH (except in rats that received cannabis and melatonin 
for 40 days) simultaneously with increased estradiol. 
This showed that the increase in GnRH by melatonin 
and vitamin C in cannabis-treated rats in this study is a 
consequence of reduced testosterone caused by these 
two agents, probably because of the absence of 
feedback inhibition of GnRH by testosterone, and 
strongly support the claim that testosterone is a potent 
feedback regulator of GnRH secretion. Similarly, the 
reductions in LH which could be accounted for by 
increased estradiol concentration closely agree with the 
contention that estradiol negative feedback on the 
pituitary gonadotropin secretion is stronger than 
testosterone feedback (Gingrich, 2010). 
Hyperprolactinemia has been extensively 
shown to be a common cause of infertility in males and 
females (Buvat, 2003; Ciccarelli et al., 2005). Previous 
study had reported indices of sexual dysfunctions in 
88% of hyperprolactinemic men, including erectile 
dysfunction, reduced sexual desire, delayed or absent 
orgasm, and retrograde ejaculation (Buvat et al., 1985). 
Hyperprolactinemia was also reported to account for 
infertility in around 11% of oligospermic males. These 
have been associated with the inhibition of pulsatile 
secretion of gonadotropin releasing hormone, which 
causes decreased release of follicle stimulating 
hormone, luteinizing hormone, and testosterone, which 
in turn causes spermatogenic arrest, impaired sperm 
motility, and altered sperm quality (Masud et al., 
2007). The present study provides additional 
information that the mechanism of gonadotoxic effect 
of CS reported by us, which we partly explained by 
oxidative stress (Alagbonsi et al., 2016), could further 
be associated with cannabis-induced 
hyperprolactinemia. 
Since HPG axis and prolactin have been 
established to play role in male fertility, we were 
curious to know if the infertility that might result from 
cannabis-induced hyperprolactinemia be associated 
with the HPG axis. The down-regulation of the 
hormones of the hypothalamic-pituitary-gonadal axis 
simultaneously with hyperprolactinemia following 
cannabis treatment in this study is in agreement with 
previous study of Masud et al. (2007) that associated 
hyperprolactinemia with reduced pulsatile secretion of 
GnRH, gonadotropins (FSH and LH), and testosterone. 
This tends to support the contention that the axis is 
involved in the hyperprolactinemia-induced infertility 
seen in cannabis treatment. 
There are many studies suggesting that 
hyperprolactinemia is one of the reversible causes of 
infertility (Soler et al., 1990; Buvat, 2003; Masud et al., 
2007). Medications such as bromocriptine and 
cabergoline, which normalizes serum prolactin levels, 
have been reported to restore gonadal function, reverse 
infertility caused by hyperprolactinemia, and induce 
reduction in prolactinoma size in the majority of 
patients (Buvat, 2003). On the contrary, co-
administration of melatonin or vitamin C with cannabis 
in the present study reversed cannabis-induced 
hyperprolactinemia without concomitantly reversing 
cannabis-induced gonadotoxicity in our previous study 
(Alagbonsi et al., 2016). 
Since the cannabis-induced hyperprolactinemia is 
related to HPG axis, we were amazed to observe that 
the reduction in prolactin was not followed by 
increased LH and FSH after melatonin or vitamin C 
was separately administered with cannabis. 
Hyperprolactinemia has been reported to directly 
influence spermatogenesis and steroidogenesis by 
acting on prolactin receptors present in Sertoli cells and 
Leydig cells in testis, and produces primary 
hypogonadism and infertility (Masud et al., 2007). In 
addition, it has been shown that oligospermic or 
azoospermic patients with normal serum levels of 
gonadotropins show relatively higher serum levels of 
prolactin, providing a role of prolactin in 
gametogenesis, which is independent of gonadotropins 
(Soler et al., 1990; Masud et al., 2007). Similarly, a 
direct, testosterone-independent effect of 
hyperprolactinemia on men’s sexual behavior has been 
documented (Bancroft et al., 1984). For instance, serum 
testosterone was reported to be in the normal range in 
nearly half of the erectile dysfunction patients with 
marked hyperprolactinemia. During treatment of 
hyperprolactinemic men with the prolactin-lowering 
agent bromocriptine, sexual improvement correlates 
better with serum prolactin decrease than with 
testosterone increase (Buvat et al., 1985). Though 
melatonin and vitamin C reversed the cannabis-induced 
hyperprolactinemia and reduction of GnRH when 
administered separately and when combined, the 
cannabis-induced reductions in LH and testosterone 
were reversed by melatonin and vitamin C only when 
combined but not when administered separately. Those 
previous reports and our present data do not rule out the 
fact that the infertility associated with cannabis-induced 
hyperprolactinemia is associated with HPG axis, but 
rather shows that combination of melatonin and vitamin 
C is required for the reversal. This is similar to our 
recent findings that show that melatonin and vitamin C 
exacerbate Cannabis sativa-induced testicular damage 
when administered separately but ameliorate it when 
combined in rats (Alagbonsi et al., 2016). 
In conclusion, this study showed that cannabis causes 
down-regulation of hypothalamic-pituitary-gonadal 
axis, endocrine disruption, and hyperprolactinemia. In 
addition, these effects (except hyperprolactinemia) can 
be reversed by melatonin and vitamin C only when 
combined but not when administered separately. 
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